133 related articles for article (PubMed ID: 24212376)
21. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
[TBL] [Abstract][Full Text] [Related]
22. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
23. Plasma profiles of lycopene after single oral and intravenous administrations in dogs.
Vertzoni M; Valsami G; Reppas C
J Pharm Pharmacol; 2006 Sep; 58(9):1211-7. PubMed ID: 16945179
[TBL] [Abstract][Full Text] [Related]
24. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs.
Lespine A; Chanoit G; Bousquet-Melou A; Lallemand E; Bassissi FM; Alvinerie M; Toutain PL
Eur J Pharm Sci; 2006 Jan; 27(1):37-43. PubMed ID: 16198549
[TBL] [Abstract][Full Text] [Related]
25. Development and Characterization of Venetoclax Nanocrystals for Oral Bioavailability Enhancement.
Kala SG; Chinni S
AAPS PharmSciTech; 2021 Mar; 22(3):92. PubMed ID: 33683477
[TBL] [Abstract][Full Text] [Related]
26. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
[TBL] [Abstract][Full Text] [Related]
27. Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.
Nader A; Minocha M; Othman AA
Clin Pharmacokinet; 2020 Mar; 59(3):335-347. PubMed ID: 31541431
[TBL] [Abstract][Full Text] [Related]
28. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
29. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
Shoemaker AR; Mitten MJ; Adickes J; Ackler S; Refici M; Ferguson D; Oleksijew A; O'Connor JM; Wang B; Frost DJ; Bauch J; Marsh K; Tahir SK; Yang X; Tse C; Fesik SW; Rosenberg SH; Elmore SW
Clin Cancer Res; 2008 Jun; 14(11):3268-77. PubMed ID: 18519752
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.
Cheung TT; Salem AH; Menon RM; Munasinghe WP; Bueno OF; Agarwal SK
Clin Pharmacol Drug Dev; 2018 May; 7(4):435-440. PubMed ID: 29058801
[TBL] [Abstract][Full Text] [Related]
31. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Salem AH; Menon RM
Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
[TBL] [Abstract][Full Text] [Related]
34. Assessing Supersaturation and Its Impact on In Vivo Bioavailability of a Low-Solubility Compound ABT-072 With a Dual pH, Two-Phase Dissolution Method.
Shi Y; Erickson B; Jayasankar A; Lu L; Marsh K; Menon R; Gao P
J Pharm Sci; 2016 Sep; 105(9):2886-2895. PubMed ID: 27321234
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
36. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
37. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
Liu H; Michmerhuizen MJ; Lao Y; Wan K; Salem AH; Sawicki J; Serby M; Vaidyanathan S; Wong SL; Agarwal S; Dunbar M; Sydor J; de Morais SM; Lee AJ
Drug Metab Dispos; 2017 Mar; 45(3):294-305. PubMed ID: 27993930
[TBL] [Abstract][Full Text] [Related]
38. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
[TBL] [Abstract][Full Text] [Related]
39. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
40. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
